2-乙酰氧基-4-氨基苯甲酸 | 102338-89-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-乙酰氧基-4-氨基苯甲酸
• 英文名称: acetyl-para-aminosalicylic acid
• 英文别名: acetyl-PAS；ACPAS；2-acetoxy-4-amino-benzoic acid；2-Acetoxy-4-amino-benzoesaeure；Acetyl 4-aminosalicylic acid；2-acetyloxy-4-aminobenzoic acid
• CAS: 102338-89-6
• 化学式: C₉H₉NO₄
• 分子量: 195.175
• InChiKey: OGBZOXBEULJKHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  89.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-乙酰氧基-4-氨基苯甲酸 、 乙酸乙酯 生成 4-乙酰氨基-2-乙酰氧基苯甲酸
  参考文献：
  名称：

  Justoni; Pessina, Il Farmaco, scienza e tecnica, 1951, vol. 6, p. 835,839

  摘要：

  DOI：
• 作为产物：
  描述：

  2-溴-4-硝基苯甲酸 在 barium dihydroxide 、 sodium hydroxide 、 copper (I) acetate 、 乙酸乙酯 、 乙酰氯 、 甲苯 、 铂 作用下， 生成 2-乙酰氧基-4-氨基苯甲酸
  参考文献：
  名称：

  Justoni; Pessina, Il Farmaco, scienza e tecnica, 1951, vol. 6, p. 835,839

  摘要：

  DOI：

文献信息

• [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS<br/>[FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2021239117A1

  公开（公告）日：2021-12-02

  Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

  本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1（DDB1）结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。
• [EN] NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES<br/>[FR] SELS, CO-CRISTAUX, ET COMPLEXES DE CO-CRISTAUX DE SELS DE NICOTINE
  申请人：REYNOLDS TOBACCO CO R

  公开号：WO2015183801A1

  公开（公告）日：2015-12-03

  The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

  该发明提供了某些尼古丁盐、共晶和盐共晶，并提供了某些尼古丁盐的新颖多形态形式。具体来说，描述了与粘酸、3,5-二羟基苯甲酸和2,3-二羟基苯甲酸结合的尼古丁盐，以及尼古丁4-乙酰氨基苯甲酸、尼古丁吉替酸和尼古丁1-羟基-2-萘酸的结晶多形态形式。该发明还提供了制备和表征这些尼古丁盐、共晶和盐共晶以及其多形态形式的方法。此外，还提供了含有尼古丁盐、共晶和/或盐共晶的烟草制品，包括吸烟物品、无烟烟草制品和电子吸烟物品。
• Drug evolution: drug design at hot spots
  申请人：Konishi Yasuo

  公开号：US20060110743A1

  公开（公告）日：2006-05-25

  A new method of designing and generating compounds having an increased probability of being drugs, drug candidates, or biologically active compounds, in particular having a therapeutic utility, is disclosed. The method consists of identifying a group of bioactive compounds, preferably of diverse therapeutic uses or biological activities and built on a common building block. In this group of compounds, side chains modifying the building block are identified and used to generate a second set of compounds according to the proposed methods of hybridization”, “single substitution” or “incorporation of frequently used side chains”. If the compounds in the second set built on the same building block contain an unusually large number of drugs, preferably with diverse therapeutic uses or biological activities, they constitute a “hot spot”. A focused combinatorial library of the “hot spot” is then generated, preferably by methods of combinatorial chemistry, and compounds of this library are screened for a variety of therapeutic uses or biological activities. The method generates drugs, drug candidates, or biologically active compounds with a high probability, without requiring any prior knowledge of biological targets.

  本文揭示了一种设计和生成化合物的新方法，这些化合物具有成为药物、药物候选物或生物活性化合物的概率增加，特别是具有治疗效用。该方法包括识别一组生物活性化合物，最好是具有不同治疗用途或生物活性，并建立在共同的基础上。在这组化合物中，识别修改基础结构的侧链，并使用“杂交”、“单一替换”或“纳入常用侧链”的建议方法生成第二组化合物。如果第二组化合物建立在相同的基础结构上，包含异常数量的药物，最好是具有不同治疗用途或生物活性，它们构成一个“热点”。然后通过组合化学的方法生成一个专注的组合式库，其中包括“热点”的化合物，并对该库中的化合物进行各种治疗用途或生物活性的筛选。该方法生成的药物、药物候选物或生物活性化合物具有高概率，无需任何先前的生物靶标知识。
• Polyphenylene ether-polyamide compositions
  申请人：GENERAL ELECTRIC COMPANY

  公开号：EP0501154A2

  公开（公告）日：1992-09-02

  Polyphenylene ethers are capped by reaction in the melt, with application of vacuum, with at least one trimellitamide, preferably phenyl 4-aminosalicylate trimellitamide. The preferred melt processing method is extrusion with vacuum venting. By this method, the polyphenylene ether is capped with reactive anhydride groups improving it therm-oxidative stability. The capped polyphenylene ether is capable of forming copolymers with polyamides and said copolymers are useful as compatibilizers for polyphenylene ether-polyamide blends.

  聚苯醚在熔体中与至少一种偏苯三甲酰胺（最好是 4-氨基水杨酸苯酯偏苯三甲酰胺）发生真空反应而封端。优选的熔融加工方法是挤出并抽真空。通过这种方法，聚苯醚会被活性酸酐基团封端，从而提高其热氧化稳定性。被封端的聚苯醚能够与聚酰胺形成共聚物，所述共聚物可用作聚苯醚-聚酰胺混合物的相容剂。
• Preparation of anhydride-capped polyphenylene ether in a melt process
  申请人：GENERAL ELECTRIC COMPANY

  公开号：EP0504560A1

  公开（公告）日：1992-09-23

  Polyphenylene ethers are capped by reaction in the melt, with application of vacuum, with at least one trimellitamide, preferably phenyl 4-aminosalicylate trimellitamide. The perferred melt processing method is extrusion with vacuum venting. By this method, the polyphenylene ether is capped with reactive anhydride groups improving its thermo-oxidative stability. The capped polyphenylene ether is capable of forming copolymers with polyamides, and said copolymers are useful as compatibilizers for polyphenylene ether-polyamide blends.

  聚苯醚在熔体中与至少一种偏苯三甲酰胺（最好是 4-氨基水杨酸苯酯偏苯三甲酰胺）发生真空反应而封端。最理想的熔体加工方法是挤出并抽真空。通过这种方法，聚苯醚会被活性酸酐基团封端，从而提高其热氧化稳定性。被封端的聚苯醚能够与聚酰胺形成共聚物，所述共聚物可用作聚苯醚-聚酰胺混合物的相容剂。